Ken Walz is co-founder and partner at Popper and Company. He has spent more than 20 years in the biotech and medical device industries in business development and finance roles and has broad experience in the structuring and negotiation of collaborative arrangements, strategy development, and financial planning and analysis.
When Warren Buffett used the phrase “skin in the game,” he referred to company managers investing in their own companies. In healthcare, we’ve discussed how equally important it is for consumers to also have some “skin in the game,” bearing at least some responsibility for their costs of care. A recent Wall Street Journal article […]
The increased use of the internet by healthcare consumers has led to at least two types of medical conversations ironically illustrated by two different online features sharing a name: the “DocTalk” here, in which Arizona kidney specialists share treatment information on smartphones, and another “DocTalk,” where Ontario physician Stuart Foxman discusses such communications issues as […]
Healthcare is drowning in chaos—from scattered data to burnout-inducing tasks. Discover how smarter workflows and real-time insights can rescue care teams and transform patient outcomes.
Last month, my colleague Shane Climie wrote a post inspired by an article in the New York Times (“How Bright Promise in Cancer Testing Fell Apart”), which exposed disturbing and cautionary insights into the application of genetic testing technology. Today, I’m responding to a recent New York Times article in which reporter Andrew Pollack wrote […]